Table 2.
The Hepatocellular Carcinoma (HCC) Status of the Transarterial Chemoembolization Plus Sorafenib and Transarterial Chemoembolization Alone Groups
| HCC Status (n/%) | TACE Plus Sorafenib (n=42) | TACE Alone(n=43) | χ2 | P |
|---|---|---|---|---|
| HCC size | 0.190 | 0.909 | ||
| >5cm | 27 (64.29%) | 26 (60.47%) | ||
| 3–5cm | 12 (28.57%) | 13 (30.23%) | ||
| <3cm | 3 (7.14%) | 4 (9.30%) | ||
| Number of tumors | 0.165 | 0.921 | ||
| >5 | 8 (19.05%) | 8 (18.60%) | ||
| 3–5 | 22 (52.38%) | 21 (48.84%) | ||
| <3 | 12 (28.57%) | 14 (32.56%) | ||
| MVI | 20 (47.62%) | 22 (51.16%) | 0.107 | 0.744 |
| EHS | 4 (9.52%) | 3 (6.97%) | 1.556 | 0.459 |
| Lung | 2 (4.76%) | 1 (2.33%) | ||
| Lymph nodes | 1 (2.38%) | 2 (4.66%) | ||
| Bone | 1 (2.38%) | 0 (0.00%) |
Abbreviations: EHS, extrahepatic spread; HCC, hepatocellular carcinoma; MVI, macroscopic vascular invasion; TACE, transarterial chemoembolization.